Triamcinolone Acetonide (Azmacort)

Subscribe to Selected New Research on Triamcinolone Acetonide

1234 relevant articles (189 outcomes, 176 trials/studies) found for this Drug

Description: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.

Also Known As:

Azmacort; Cinonide; Kenacort A; Kenalog; Kenalog 40; Tricort-40; 40, Kenalog; A, Kenacort; Acetonide, Triamcinolone; Tricort 40; Tricort40; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-

Relationship Network

Drug Context: Research Results

Experts

1.	Jonas, Jost B: 26 articles (07/2008 - 09/2002)
2.	Jonas, J B: 13 articles (03/2007 - 03/2003)
3.	Kreissig, Ingrid: 11 articles (06/2006 - 09/2002)
4.	Degenring, Robert F: 10 articles (08/2006 - 09/2002)
5.	Kamppeter, Bernd A: 8 articles (08/2006 - 07/2004)
6.	Ozdemir, Hakan: 7 articles (05/2006 - 08/2004)
7.	Karacorlu, Murat: 7 articles (05/2006 - 08/2004)
8.	Degenring, R F: 7 articles (01/2006 - 03/2003)
9.	Kreissig, I: 7 articles (01/2006 - 04/2003)
10.	Scott, Ingrid U: 6 articles (10/2006 - 10/2003)

Related Diseases

1.	Macular Edema 07/01/2004 - "This information may be helpful in determining the optimal dosage of intravitreal triamcinolone acetonide for the treatment of diffuse diabetic macular edema." 05/01/2008 - "PURPOSE:: To determine safety and efficacy of intravitreal triamcinolone acetonide (IVTA) for refractory clinically significant diabetic macular edema (DME). " 01/01/2007 - "CONCLUSION: Intravitreal injection of triamcinolone acetonide leads to a significant improvement of mean VA in patients with macular edema due to CRVO. " 06/01/2006 - "CONCLUSIONS: Intravitreal injection of triamcinolone acetonide for clinically significant diabetic macular edema is effective in reducing foveal thickness and improving visual acuity in the short term. " 05/01/2005 - "CONCLUSION: A single injection of 4 mg of intravitreal triamcinolone acetonide effectively reduces the foveal thickness in diabetic macular edema and improves visual acuity, but there does not appear to be a strong correlation between the reduction of foveal thickness and the improvement in visual acuity." Order ALL the reference details at left...
2.	Macular Degeneration (Age-Related Maculopathy) 06/01/2001 - "Animal models, in vitro assays and pilot clinical studies suggest that intravitreal triamcinolone acetonide may be useful in the treatment of age-related macular degeneration. " 09/01/2000 - "Whilst animal studies and a pilot clinical trial suggest that intravitreal triamcinolone acetonide (TA) may be useful in the treatment of age-related macular degeneration (AMD), its mode of action remains to be fully elucidated. " 01/01/2006 - "PURPOSE: To evaluate the efficacy of sub-Tenon's injection of triamcinolone acetonide for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). " 01/01/2000 - "CONCLUSIONS: Intravitreal triamcinolone acetonide may provide short-term improvement in visual acuity and fundus findings in exudative macular degeneration. " 10/01/2006 - "OBJECTIVE: The aim of this study was to compare the visual acuity change after an intravitreal high-dose injection of triamcinolone acetonide (TA) in various types of exudative age-related macular degeneration (AMD). " Order ALL the reference details at left...
3.	Asthma (Bronchial Asthma) 07/01/1978 - "The results of therapy were excellent (total disappearance of asthmatic manifestations) or good (considerable improvement of asthma symptoms) in 88.3% of treated cases, while in 11.7% of patients, Kenalog had no effect. " 01/01/1982 - "Aerosolized triamcinolone acetonide was therefore considered a safe and effective modality in the management of chronic asthma." 09/01/1997 - "Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma." 04/01/1998 - "OBJECTIVE: We sought to evaluate the safety and efficacy of 400 microg twice daily triamcinolone acetonide (TAA) compared with placebo in adult patients with mild-to-moderate asthma who were poorly controlled by beta2-agonist therapy. " 11/01/1999 - "A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. " Order ALL the reference details at left...
4.	Retinal Vein Occlusion 01/01/2008 - "PURPOSE: To assess the long-term safety and efficacy of intravitreal triamcinolone acetonide injection in the management of macular oedema caused by central, hemi-, and branch retinal vein occlusion (CRVO, HRVO, or BRVO). " 11/01/2008 - "CONCLUSION: This study demonstrates a benefit associated with intravitreal triamcinolone acetonide injection for retinal vein occlusions that was maintained by patients with branch retinal vein occlusions and hemiretinal vein occlusions over a 12-month period. " 01/01/2008 - "BACKGROUND: The aim of the study was to evaluate the safety and effectiveness of trans-Tenon's retrobulbar triamcinolone acetonide (TA) injection for macular oedema associated with branch retinal vein occlusion (BRVO). " 07/01/2008 - "CONCLUSION: A high-dose (25 mg) intravitreal triamcinolone acetonide injection induces the progression of cortical and posterior subcapsular opacity in patients with diabetic macular oedema and retinal vein occlusion." 01/01/2008 - "CONCLUSIONS: Intravitreal injection of triamcinolone acetonide is effective as a short-term treatment of macular oedema owing to retinal vein occlusion, improving both visual acuity and macular thickness. " Order ALL the reference details at left...
5.	Rhinitis 10/01/2000 - "Triamcinolone acetonide at standard dosages (110 or 220microg once or twice a day) does not appear to suppress adrenal gland function and is effective in relieving most symptoms of allergic rhinitis. " 03/01/1994 - "All three doses of triamcinolone acetonide were associated with sustained improvement in allergic rhinitis symptoms over the course of 1 year, as evidenced by physicians' and patients' global evaluations, ratings of the nasal environment (appearance and color of the nasal mucosa, as well as the quality of nasal secretions), nasal eosinophil counts, and requirement for escape medication. " 05/01/2006 - "The intranasal corticosteroid triamcinolone acetonide (TAA) is an effective treatment for allergic rhinitis (AR). " 03/01/1996 - "When pollen counts were correlated to mean nasal rhinitis scores, the triamcinolone acetonide group showed continued improvement from week 1 to week 2 in nasal symptoms when pollen counts were at their highest. " 05/01/2006 - "BACKGROUND: In this study we aimed to investigate the effect of triamcinolone acetonide aqueous (TAA) intranasal spray that was used for 2 months to treat allergic rhinitis (AR) on the nasal carriage of Staphylococcus aureus (NCSA). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Retinaldehyde (Retinal)
2.	Triamcinolone Acetonide (Azmacort)
3.	1-phenyl-3,3-dimethyltriazene (PDT)
4.	verteporfin (Visudyne)
5.	fluticasone (Cutivate)
6.	Adrenal Cortex Hormones (Corticosteroids)
7.	Beclomethasone (Beclometasone)
8.	Loratadine (Alavert)
9.	Steroids
10.	Budesonide (Pulmicort)

Related Therapies and Procedures

1.	Light Coagulation
2.	Vitrectomy
3.	Lasers (Laser)
4.	Photochemotherapy (Photodynamic Therapy)
5.	Injections

Best Treatments:
Research Summary Report
on Macular Edema

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 298 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>